12月12日 - Genmab A/S宣布完成对Merus N.V.未流通普通股的要约收购，并正式开始后续要约期。Genmab预计将在2027年推出Petosemtamab，并计划扩展和加速Petosemtamab的研发，未来可能拓展至其他治疗领域。Genmab相信，Petosemtamab将在2029年前能为EBITDA带来正面贡献，并具备每年十亿美元的销售潜力。94.2%的Merus股份已在Genmab的要约中被提交。
12月12日 - Genmab A/S宣布完成对Merus N.V.未流通普通股的要约收购，并正式开始后续要约期。Genmab预计将在2027年推出Petosemtamab，并计划扩展和加速Petosemtamab的研发，未来可能拓展至其他治疗领域。Genmab相信，Petosemtamab将在2029年前能为EBITDA带来正面贡献，并具备每年十亿美元的销售潜力。94.2%的Merus股份已在Genmab的要约中被提交。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.